Vaccitech PLC
Change company Symbol lookup
Select an option...
VACC Vaccitech PLC
PNR Pentair PLC
AAL American Airlines Group Inc
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
ARTW Art's Way Manufacturing Co Inc

Health Care : Biotechnology |
Based in United Kingdom
Company profile

Vaccitech plc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Day's Change
-0.2236 (-9.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

Today's volume of 168,452 shares is on pace to be much greater than VACC's 10-day average volume of 164,005 shares.


Costco stock bounces off 6-month low after upbeat December sales

7:34 am ET January 6, 2023 (MarketWatch)

Shares of Costco Wholesale Corp. (COST) bounced 2.2% off a 6 1/2-month low in premarket trading Friday, after the membership-based warehouse retailer reported upbeat December sales. The company reported late Thursday net sales of $23.80 billion for the month of December, up 7.0% from the same period a year ago. For the five weeks to Jan. 1, comparable-store sales (comps) excluding gasoline sales and currency impacts rose 7.3% from a year ago. That compares with a 5.3% rise in November, the FactSet consensus for the fiscal second-quarter through February of 5.2%. "This is the first major retailer to provide an indication of December results and the rebound versus November to better-than-expected comps endorses the theory that holiday sales came late in 2022 after a slow start in November," D.A. Davidson analyst Michael Baker wrote in a note to clients. He reiterated his neutral rating on the stock but raised his price target to $478 from $423. The stock, which closed Thursday at the lowest price since June 17, 2022, has lost 6.7% over the past three months, while the SPDR Consumer Staples Select Sector ETF (XLP) has rallied 9.3% and the S&P 500 has gained 1.7%.

-Tomi Kilgore


(END) Dow Jones Newswires

January 06, 2023 07:34 ET (12:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.